GxPinnacle Logo

Pharmacovigilance Regulatory Expectations

What Do Inspectors Check for Pharmacovigilance KPI Review Meetings and Oversight?

Pharmacovigilance systems must demonstrate oversight through structured KPI review meetings. Regulators expect organisations to review performance metrics, document decisions, and implement actions where compliance or safety risks are identified.

Founders, CEOs & MDsPV LeadsQA/ComplianceScientists tasked with documentation

The short version

What teams need to understand

  • Pharmacovigilance systems should review KPI performance through structured governance meetings.
  • KPI review meetings should assess performance against targets and identify deviations.
  • Meeting discussions, decisions, and actions must be documented.
  • Oversight meetings should involve PV leadership and relevant stakeholders.
  • Performance issues identified through KPI monitoring must be escalated and addressed.
  • Inspection-ready evidence should demonstrate that KPI results are actively reviewed and acted upon.

Regulatory expectation

What regulators expect

Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.

  • PV systems must review KPI performance through governance processes.
  • KPI review meetings must assess performance against defined targets.
  • Decisions and actions must be documented.
  • Performance issues must trigger escalation and corrective action.
  • Oversight must involve appropriate PV leadership and governance structures.

Why it matters

What this means in practice

Inspectors assess whether pharmacovigilance systems review KPI performance through structured governance meetings. They typically examine meeting agendas, minutes, decisions, and action tracking to confirm that performance monitoring leads to oversight and continuous improvement.

Questions this page answers

What oversight meetings do inspectors expect in pharmacovigilance?
How should PV KPIs be reviewed?
What evidence shows PV governance meetings?
How do inspectors assess pharmacovigilance oversight?
What should be discussed in PV KPI meetings?
What documentation proves KPI review meetings?
How often should PV governance meetings occur?
What is expected in PV oversight meetings?
How do inspectors verify PV governance?
What minutes are required for pharmacovigilance meetings?

Inspection evidence

Evidence teams should be able to show

PV KPI Review Meeting Agenda

  • Monthly KPI review meeting agenda
  • Defined meeting objectives and scope
  • List of KPI categories reviewed
  • Participant list including PV leadership and QPPV

PV KPI Meeting Minutes

  • Documented discussion of KPI performance
  • Summary of deviations from targets
  • Decisions made during the meeting
  • Assigned action items and responsibilities

Action Tracking Logs

  • List of actions arising from KPI reviews
  • Assigned owners and due dates
  • Status tracking of open and closed actions
  • Evidence of follow-up and completion

Governance Structure Evidence

  • Defined governance committees or forums
  • Roles and responsibilities of attendees
  • Defined frequency of KPI review meetings
  • Escalation pathways for critical issues

Regulatory Basis (Primary Sources)

  • GVP Module I - pharmacovigilance systems must include management review and oversight
  • GVP Module IV - PV audits and governance expectations
  • ICH E2D - monitoring and review of safety reporting processes
  • ICH E2E - pharmacovigilance system oversight and performance review
  • MHRA GPvP guidance - expectations for PV system governance and oversight
  • FDA pharmacovigilance guidance - oversight of safety system performance

Typical Inspection Questions (What Inspectors Ask)

  • Show me your pharmacovigilance KPI review meeting minutes.
  • How often do you review KPI performance?
  • What actions were taken following KPI deviations?
  • Who attends your PV governance meetings?
  • How do KPI reviews influence decision-making?

Common failure patterns

KPI review meetings are not performed regularly or not documented.
Meeting minutes do not capture decisions or actions.
KPI deviations are discussed but no actions are assigned.
Governance meetings occur but lack meaningful review of performance data.
No evidence that KPI review leads to improvements.

What good looks like

  • Regular KPI review meetings with defined agendas.
  • Clear documentation of KPI performance and discussion points.
  • Action items assigned with owners and deadlines.
  • Evidence that KPI deviations trigger investigation and improvement.
  • Active involvement of PV leadership in governance meetings.

How teams operationalise it

  • Schedule regular KPI review meetings (e.g. monthly).
  • Define a standard agenda covering all PV KPI categories.
  • Document meeting minutes including decisions and actions.
  • Assign responsibility for each action item.
  • Track action completion and follow-up in subsequent meetings.
  • Ensure KPI reviews inform governance and decision-making.

From expectation to working control

Find the documentation that supports this work

Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.

Browse pharmacovigilance toolkitsView related toolkit

Frequently asked questions

How often should pharmacovigilance KPI meetings be held?

KPI review meetings are typically held monthly, with additional oversight reviews at a senior management level periodically.

What should be included in PV KPI meeting minutes?

Minutes should include KPI performance results, discussion of deviations, decisions made, and clearly assigned action items.

Do inspectors review KPI meeting minutes?

Yes. Inspectors frequently request meeting minutes to confirm that KPI monitoring leads to active oversight and decision-making.

Who should attend KPI governance meetings?

Meetings typically include the QPPV, PV leadership, and functional leads responsible for KPI areas.

What happens when KPI performance is below target?

Deviations should trigger investigation, escalation, and corrective or preventive actions as part of the PV quality system.

How do inspectors verify KPI oversight?

Inspectors review meeting records, action logs, and evidence that KPI discussions result in meaningful actions and improvements.

Source boundary

Regulatory sources

These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.

European Medicines Agency (EMA)

  • Good pharmacovigilance practices (GVP)

    View source

  • Guideline on good pharmacovigilance practices (GVP) - Module I

    View source

FDA

ICH

MHRA